.png)
Oligonucleotide Api Market by Product Type and Application- Global Industry Analysis & Forecast to 2027
Published On : November 2020 Pages : 158 Category: Pharma & Healthcare Report Code : HC1213807
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Oligonucleotide Api Market by Product Type (Antisense Oligonucleotides API, Short Interfering RNA (siRNA) API, Phosphorodiamidate Morpholino Oligonucleotides (PMO) API, MiRNA API, Aptamers API, CpG Oligonucleotides API, Others (ON Conjugates (NP), ShRNA, etc.) and Application (Contract Manufacturing Organizations (CMOs), Pharmaceutical Companies, Biopharmaceutical Companies, Contract Development & Manufacturing Organizations (CDMOs) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Oligonucleotide Api Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Oligonucleotide Apiare DNA or RNA molecules, oligomers, that have a wide range of .applications in genetic testing, research, and forensics. These Api are made in the laboratory by solid-phase chemical synthesis, and these small bits of nucleic acids can be manufactured as single-stranded molecules.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Oligonucleotide Api Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Agilent Technologies, Inc.
- Bachem Holding AG
- CordenPharma International
- Integrated DNA Technologies, Inc. (Danaher Corporation)
- Eurofins Scientific
- GE Healthcare
- Merck KGaA
- Thermo Fisher Scientific
- RiBoBio Co.
- LGC Biosearch Technologies
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Oligonucleotide Api Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Antisense Oligonucleotides API
o Short Interfering RNA (siRNA) API
o Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
o MiRNA API
o Aptamers API
o CpG Oligonucleotides API
o Others (ON Conjugates (NP), ShRNA, etc.)
· Oligonucleotide Api Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Contract Manufacturing Organizations (CMOs)
o Pharmaceutical Companies
o Biopharmaceutical Companies
o Contract Development & Manufacturing Organizations (CDMOs)
· Oligonucleotide Api Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Agilent Technologies, Inc.
o Bachem Holding AG
o CordenPharma International
o Integrated DNA Technologies, Inc. (Danaher Corporation)
o Eurofins Scientific
o GE Healthcare
o Merck KGaA
o Thermo Fisher Scientific
o RiBoBio Co.
o LGC Biosearch Technologies
· Oligonucleotide Api Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Oligonucleotide Api Market, By Country
o U.S. Oligonucleotide Api Market
o Canada Oligonucleotide Api Market
o Mexico Oligonucleotide Api Market
o Europe
§ Europe Oligonucleotide Api Market, By Country
o UK Oligonucleotide Api Market
o Germany Oligonucleotide Api Market
o France Oligonucleotide Api Market
o Russia Oligonucleotide Api Market
o Italy Oligonucleotide Api Market
o Rest of Europe Oligonucleotide Api Market
o Asia-Pacific
§ Asia-Pacific Oligonucleotide Api Market, By Country
o China Oligonucleotide Api Market
o Japan Oligonucleotide Api Market
o South Korea Oligonucleotide Api Market
o India Oligonucleotide Api Market
o Southeast Asia Oligonucleotide Api Market
o Rest of Asia-Pacific Oligonucleotide Api Market
o South America
§ South America Oligonucleotide Api Market
o Brazil Oligonucleotide Api Market
o Argentina Oligonucleotide Api Market
o Columbia Oligonucleotide Api Market
o Rest of South America Oligonucleotide Api Market
o Middle East and Africa
§ Middle East and Africa Oligonucleotide Api Market
o Saudi Arabia Oligonucleotide Api Market
o UAE Oligonucleotide Api Market
o Egypt Oligonucleotide Api Market
o Nigeria Oligonucleotide Api Market
o South Africa Oligonucleotide Api Market
o TurkeyOligonucleotide Api Market
o Rest of MEA Oligonucleotide Api Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Oligonucleotide Api Market, By Product Type
5.1. Introduction
5.2. Global Oligonucleotide Api Revenue and Market Share by Product Type (2017-2021)
5.2.1. Global Oligonucleotide Api Revenue and Revenue Share by Product Type (2017-2021)
5.3. Antisense Oligonucleotides API
5.3.1. Global Antisense Oligonucleotides API Revenue and Growth Rate (2017-2021)
5.4. Short Interfering RNA (siRNA) API
5.4.1. Global Short Interfering RNA (siRNA) API Revenue and Growth Rate (2017-2021)
5.5. Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
5.5.1. Global Phosphorodiamidate Morpholino Oligonucleotides (PMO) API Revenue and Growth Rate (2017-2021)
5.6. MiRNA API
5.6.1. Global MiRNA API Revenue and Growth Rate (2017-2021)
5.7. Aptamers API
5.7.1. Global Aptamers API Revenue and Growth Rate (2017-2021)
5.8. CpG Oligonucleotides API
5.8.1. Global CpG Oligonucleotides API Revenue and Growth Rate (2017-2021)
5.9. Others (ON Conjugates (NP), ShRNA, etc.)
5.9.1. Global Others (ON Conjugates (NP), ShRNA, etc.) Revenue and Growth Rate (2017-2021)
6. Oligonucleotide Api Market, By Applications
6.1. Introduction
6.2. Global Oligonucleotide Api Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Oligonucleotide Api Revenue and Revenue Share by Applications (2017-2021)
6.3. Contract Manufacturing Organizations (CMOs)
6.3.1. Global Contract Manufacturing Organizations (CMOs) Revenue and Growth Rate (2017-2021)
6.4. Pharmaceutical Companies
6.4.1. Global Pharmaceutical Companies Revenue and Growth Rate (2017-2021)
6.5. Biopharmaceutical Companies
6.5.1. Global Biopharmaceutical Companies Revenue and Growth Rate (2017-2021)
6.6. Contract Development & Manufacturing Organizations (CDMOs)
6.6.1. Global Contract Development & Manufacturing Organizations (CDMOs) Revenue and Growth Rate (2017-2021)
7. Oligonucleotide Api Market, By Region
7.1. Introduction
7.2. Global Oligonucleotide Api Revenue and Market Share by Regions
7.2.1. Global Oligonucleotide Api Revenue by Regions (2017-2021)
7.3. North America Oligonucleotide Api by Countries
7.3.1. North America Oligonucleotide Api Revenue and Growth Rate (2017-2021)
7.3.2. North America Oligonucleotide Api Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Oligonucleotide Api by Countries
7.4.1. Europe Oligonucleotide Api Revenue and Growth Rate (2017-2021)
7.4.2. Europe Oligonucleotide Api Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Oligonucleotide Api by Countries
7.5.1. Asia-Pacific Oligonucleotide Api Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Oligonucleotide Api Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Oligonucleotide Api by Countries
7.6.1. South America Oligonucleotide Api Revenue and Growth Rate (2017-2021)
7.6.2. South America Oligonucleotide Api Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Oligonucleotide Api by Countries
7.7.1. Middle East and Africa Oligonucleotide Api Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Oligonucleotide Api Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Agilent Technologies, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Bachem Holding AG
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. CordenPharma International
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Integrated DNA Technologies, Inc. (Danaher Corporation)
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Eurofins Scientific
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. GE Healthcare
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Merck KGaA
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Thermo Fisher Scientific
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. RiBoBio Co.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. LGC Biosearch Technologies
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Oligonucleotide Api Market Forecast (2022-2027)
9.1. Global Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Oligonucleotide Api Market Forecast by Regions (2022-2027)
9.2.1. North America Oligonucleotide Api Market Forecast (2022-2027)
9.2.1.1. United States Oligonucleotide Api Market Forecast (2022-2027)
9.2.1.2. Canada Oligonucleotide Api Market Forecast (2022-2027)
9.2.1.3. Mexico Oligonucleotide Api Market Forecast (2022-2027)
9.2.2. Europe Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.1. Germany Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.2. France Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.3. UK Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.4. Russia Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.5. Italy Oligonucleotide Api Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Oligonucleotide Api Market Forecast (2022-2027)
9.2.3. Asia-Pacific Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.1. China Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.2. Japan Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.3. Korea Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.4. India Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Oligonucleotide Api Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Oligonucleotide Api Market Forecast (2022-2027)
9.2.4. South America Oligonucleotide Api Market Forecast (2022-2027)
9.2.4.1. Brazil Oligonucleotide Api Market Forecast (2022-2027)
9.2.4.2. Argentina Oligonucleotide Api Market Forecast (2022-2027)
9.2.4.3. Columbia Oligonucleotide Api Market Forecast (2022-2027)
9.2.4.4. Rest of South America Oligonucleotide Api Market Forecast (2022-2027)
9.2.5. Middle East and Africa Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.3. Egypt Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.4. Nigeria Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.5. South Africa Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.6. Turkey Oligonucleotide Api Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Oligonucleotide Api Market Forecast (2022-2027)
9.3. Oligonucleotide Api Market Forecast by Product Type (2022-2027)
9.3.1. Oligonucleotide Api Forecast by Product Type (2022-2027)
9.3.2. Oligonucleotide Api Market Share Forecast by Product Type (2022-2027)
9.4. Oligonucleotide Api Market Forecast by Applications (2022-2027)
9.4.1. Oligonucleotide Api Forecast by Applications (2022-2027)
9.4.2. Oligonucleotide Api Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Oligonucleotide Api Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Oligonucleotide Api Revenue and Revenue Share by Product Type (2017-2019)
Figure Global Antisense Oligonucleotides API Revenue and Growth Rate (2017-2019)
Figure Global Short Interfering RNA (siRNA) API Revenue and Growth Rate (2017-2019)
Figure Global Phosphorodiamidate Morpholino Oligonucleotides (PMO) API Revenue and Growth Rate (2017-2019)
Figure Global MiRNA API Revenue and Growth Rate (2017-2019)
Figure Global Aptamers API Revenue and Growth Rate (2017-2019)
Figure Global CpG Oligonucleotides API Revenue and Growth Rate (2017-2019)
Figure Global Others (ON Conjugates (NP), ShRNA, etc.) Revenue and Growth Rate (2017-2019)
Table Global Oligonucleotide Api Revenue and Revenue Share by Applications (2017-2019)
Figure Global Contract Manufacturing Organizations (CMOs) Revenue and Growth Rate (2017-2019)
Figure Global Pharmaceutical Companies Revenue and Growth Rate (2017-2019)
Figure Global Biopharmaceutical Companies Revenue and Growth Rate (2017-2019)
Figure Global Contract Development & Manufacturing Organizations (CDMOs) Revenue and Growth Rate (2017-2019)
Table Global Oligonucleotide Api Revenue by Regions (2017-2019)
Figure North America Oligonucleotide Api Growth Rate (2017-2019)
Figure North America Oligonucleotide Api Revenue and Growth Rate (2017-2019)
Figure North America Oligonucleotide Api by Countries (2017-2019)
Figure North America Oligonucleotide Api Revenue (Million USD) by Countries (2017-2019)
Figure United States Oligonucleotide Api Growth Rate (2017-2019)
Figure United States Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Oligonucleotide Api Growth Rate (2017-2019)
Figure Canada Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Oligonucleotide Api Growth Rate (2017-2019)
Figure Mexico Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Oligonucleotide Api Growth Rate (2017-2019)
Figure Europe Oligonucleotide Api Revenue and Growth Rate (2017-2019)
Figure Europe Oligonucleotide Api by Countries (2017-2019)
Figure Europe Oligonucleotide Api Revenue (Million USD) by Countries (2017-2019)
Figure Germany Oligonucleotide Api Growth Rate (2017-2019)
Figure Germany Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Oligonucleotide Api Growth Rate (2017-2019)
Figure France Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Oligonucleotide Api Growth Rate (2017-2019)
Figure UK Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Oligonucleotide Api Growth Rate (2017-2019)
Figure Russia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Oligonucleotide Api Growth Rate (2017-2019)
Figure Italy Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Oligonucleotide Api Growth Rate (2017-2019)
Figure Rest of Europe Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Oligonucleotide Api Growth Rate (2017-2019)
Figure Asia-Pacific Oligonucleotide Api Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Oligonucleotide Api by Countries (2017-2019)
Figure Asia-Pacific Oligonucleotide Api Revenue (Million USD) by Countries (2017-2019)
Figure China Oligonucleotide Api Growth Rate (2017-2019)
Figure China Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Oligonucleotide Api Growth Rate (2017-2019)
Figure Japan Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Oligonucleotide Api Growth Rate (2017-2019)
Figure Korea Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Oligonucleotide Api Growth Rate (2017-2019)
Figure India Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Oligonucleotide Api Growth Rate (2017-2019)
Figure Southeast Asia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oligonucleotide Api Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Oligonucleotide Api Growth Rate (2017-2019)
Figure South America Oligonucleotide Api Revenue and Growth Rate (2017-2019)
Figure South America Oligonucleotide Api by Countries (2017-2019)
Figure South America Oligonucleotide Api Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Oligonucleotide Api Growth Rate (2017-2019)
Figure Brazil Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Oligonucleotide Api Growth Rate (2017-2019)
Figure Argentina Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Oligonucleotide Api Growth Rate (2017-2019)
Figure Columbia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Oligonucleotide Api Growth Rate (2017-2019)
Figure Rest of South America Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Oligonucleotide Api Growth Rate (2017-2019)
Figure Middle East and Africa Oligonucleotide Api Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Oligonucleotide Api by Countries (2017-2019)
Figure Middle East and Africa Oligonucleotide Api Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Oligonucleotide Api Growth Rate (2017-2019)
Figure Saudi Arabia Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Oligonucleotide Api Growth Rate (2017-2019)
Figure United Arab Emirates Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Oligonucleotide Api Growth Rate (2017-2019)
Figure Egypt Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Oligonucleotide Api Growth Rate (2017-2019)
Figure Nigeria Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Oligonucleotide Api Growth Rate (2017-2019)
Figure South Africa Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Oligonucleotide Api Growth Rate (2017-2019)
Figure Turkey Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oligonucleotide Api Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2017-2019)
Table Agilent Technologies, Inc. Oligonucleotide Api Financial Overview
Table Bachem Holding AG Oligonucleotide Api Financial Overview
Table CordenPharma International Oligonucleotide Api Financial Overview
Table Integrated DNA Technologies, Inc. (Danaher Corporation) Oligonucleotide Api Financial Overview
Table Eurofins Scientific Oligonucleotide Api Financial Overview
Table GE Healthcare Oligonucleotide Api Financial Overview
Table Merck KGaA Oligonucleotide Api Financial Overview
Table Thermo Fisher Scientific Oligonucleotide Api Financial Overview
Table RiBoBio Co. Oligonucleotide Api Financial Overview
Table LGC Biosearch Technologies Oligonucleotide Api Financial Overview
Figure Global Oligonucleotide Api Revenue (Millions USD) and Growth Rate (2019-2027)
Table Oligonucleotide Api Market Forecast by Regions (2019-2027)
Figure North America Oligonucleotide Api Market Forecast (2019-2027)
Figure United States Oligonucleotide Api Market Forecast (2019-2027)
Figure Canada Oligonucleotide Api Market Forecast (2019-2027)
Figure Mexico Oligonucleotide Api Market Forecast (2019-2027)
Figure Europe Oligonucleotide Api Market Forecast (2019-2027)
Figure Germany Oligonucleotide Api Market Forecast (2019-2027)
Figure France Oligonucleotide Api Market Forecast (2019-2027)
Figure UK Oligonucleotide Api Market Forecast (2019-2027)
Figure Russia Oligonucleotide Api Market Forecast (2019-2027)
Figure Italy Oligonucleotide Api Market Forecast (2019-2027)
Figure Rest of Europe Oligonucleotide Api Market Forecast (2019-2027)
Figure Asia-Pacific Oligonucleotide Api Market Forecast (2019-2027)
Figure China Oligonucleotide Api Market Forecast (2019-2027)
Figure Japan Oligonucleotide Api Market Forecast (2019-2027)
Figure Korea Oligonucleotide Api Market Forecast (2019-2027)
Figure India Oligonucleotide Api Market Forecast (2019-2027)
Figure Southeast Asia Oligonucleotide Api Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Oligonucleotide Api Market Forecast (2019-2027)
Figure South America Oligonucleotide Api Market Forecast (2019-2027)
Figure Brazil Oligonucleotide Api Market Forecast (2019-2027)
Figure Argentina Oligonucleotide Api Market Forecast (2019-2027)
Figure Columbia Oligonucleotide Api Market Forecast (2019-2027)
Figure Rest of South America Oligonucleotide Api Market Forecast (2019-2027)
Figure Middle East and Africa Oligonucleotide Api Market Forecast (2019-2027)
Figure Saudi Arabia Oligonucleotide Api Market Forecast (2019-2027)
Figure United Arab Emirates Oligonucleotide Api Market Forecast (2019-2027)
Figure Egypt Oligonucleotide Api Market Forecast (2019-2027)
Figure Nigeria Oligonucleotide Api Market Forecast (2019-2027)
Figure South Africa Oligonucleotide Api Market Forecast (2019-2027)
Figure Turkey Oligonucleotide Api Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Oligonucleotide Api Market Forecast (2019-2027)
Figure Global Oligonucleotide Api Forecast by Product Type (2019-2027)
Figure Global Oligonucleotide Api Market Share Forecast by Product Type (2019-2027)
Figure Global Oligonucleotide Api Forecast by Product Type (2019-2027)
Figure Global Oligonucleotide Api Forecast by Applications (2019-2027)
Figure Global Oligonucleotide Api Market Share Forecast by Applications (2019-2027)
Figure Global Oligonucleotide Api Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|